Literature DB >> 17578786

Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.

Amita Gupta1, Uma Nayak, Malathi Ram, Ramesh Bhosale, Sandesh Patil, Anita Basavraj, Arjun Kakrani, Sheeja Philip, Dipali Desai, Jayagowri Sastry, Robert C Bollinger.   

Abstract

BACKGROUND: In contrast with many other countries, isoniazid preventative therapy is not recommended in clinical care guidelines for human immunodeficiency virus (HIV)-infected persons with latent tuberculosis (TB) in India.
METHODS: Seven hundred fifteen HIV-infected mothers and their infants were prospectively followed up for 1 year after delivery at a public hospital in Pune, India. Women were evaluated for active TB during regular clinic visits, and tuberculin skin tests were performed. World Health Organization definitions for confirmed, probable, and presumed TB were used. Poisson regression was performed to determine correlates of incident TB, and adjusted probabilities of mortality were calculated.
RESULTS: Twenty-four of 715 HIV-infected women who were followed up for 480 postpartum person-years developed TB, yielding a TB incidence of 5.0 cases per 100 person-years (95% confidence interval [CI], 3.2-7.4 cases per 100 person-years). Predictors of incident TB included a baseline CD4 cell count <200 cells/mm(3) (adjusted incident rate ratio [IRR], 7.58; 95% CI, 3.07-18.71), an HIV load >50,000 copies/mL (adjusted IRR, 3.92; 95% CI, 1.69-9.11), and a positive tuberculin skin test result (adjusted IRR, 3.08; 95% CI, 1.27-7.47). Three (12.5%) of 24 women with TB died, compared with 7 (1.0%) of 691 women without TB (IRR, 12.2; 95% CI, 2.03-53.33). Among 23 viable infants with mothers with TB, 2 received a diagnosis of TB. Four infants with mothers with TB died, compared with 28 infants with mothers without TB (IRR, 4.71; 95% CI, 1.19-13.57). Women with incident TB and their infants had a 2.2- and 3.4-fold increased probability of death, respectively, compared with women without active TB and their infants, controlling for factors independently associated with mortality (adjusted IRR, 2.2 [95% CI, 0.6-3.8] and 3.4 [95% CI, 1.22-10.59], respectively).
CONCLUSIONS: Among Indian HIV-infected women, we found a high incidence of postpartum TB and associated postpartum maternal and infant death. Active screening and targeted use of isoniazid preventative therapy among HIV-infected women in India should be considered to prevent postpartum maternal TB and associated mother-to-child morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17578786     DOI: 10.1086/518974

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  59 in total

1.  Verification bias in a diagnostic accuracy study of symptom screening for tuberculosis in HIV-infected pregnant women.

Authors:  Colleen F Hanrahan; Daniel Westreich; Annelies Van Rie
Journal:  Clin Infect Dis       Date:  2012-03-14       Impact factor: 9.079

2.  Cost-effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India.

Authors:  S Kapoor; A Gupta; M Shah
Journal:  Int J Tuberc Lung Dis       Date:  2016-01       Impact factor: 2.373

3.  Effect of Pregnancy on Interferon Gamma Release Assay and Tuberculin Skin Test Detection of Latent TB Infection Among HIV-Infected Women in a High Burden Setting.

Authors:  Sylvia M LaCourse; Lisa M Cranmer; Daniel Matemo; John Kinuthia; Barbra A Richardson; David J Horne; Grace John-Stewart
Journal:  J Acquir Immune Defic Syndr       Date:  2017-05-01       Impact factor: 3.731

4.  Predictive value of interferon-gamma release assays for postpartum active tuberculosis in HIV-1-infected women.

Authors:  S R Jonnalagadda; E Brown; B Lohman-Payne; D Wamalwa; C Farquhar; G C John-Stewart
Journal:  Int J Tuberc Lung Dis       Date:  2013-12       Impact factor: 2.373

5.  Tryptophan catabolism reflects disease activity in human tuberculosis.

Authors:  Jeffrey M Collins; Amnah Siddiqa; Dean P Jones; Ken Liu; Russell R Kempker; Azhar Nizam; N Sarita Shah; Nazir Ismail; Samuel G Ouma; Nestani Tukvadze; Shuzhao Li; Cheryl L Day; Jyothi Rengarajan; James Cm Brust; Neel R Gandhi; Joel D Ernst; Henry M Blumberg; Thomas R Ziegler
Journal:  JCI Insight       Date:  2020-05-21

6.  Symptom screening among HIV-infected pregnant women is acceptable and has high negative predictive value for active tuberculosis.

Authors:  Amita Gupta; Aditya Chandrasekhar; Nikhil Gupte; Sandesh Patil; Ramesh Bhosale; Pradeep Sambarey; Shivahari Ghorpade; Uma Nayak; Laila Garda; Jayagowri Sastry; Renu Bharadwaj; Robert C Bollinger
Journal:  Clin Infect Dis       Date:  2011-09-21       Impact factor: 9.079

7.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

8.  Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.

Authors:  Ruth N Moro; Nigel A Scott; Andrew Vernon; Naomi K Tepper; Stefan V Goldberg; Kevin Schwartzman; Chi-Chiu Leung; Neil W Schluger; Robert W Belknap; Richard E Chaisson; Masahiro Narita; Elizabeth S Machado; Marta Lopez; Jorge Sanchez; Margarita E Villarino; Timothy R Sterling
Journal:  Ann Am Thorac Soc       Date:  2018-05

9.  HIV and maternal mortality.

Authors:  Eva Lathrop; Denise J Jamieson; Isabella Danel
Journal:  Int J Gynaecol Obstet       Date:  2014-07-17       Impact factor: 3.561

10.  Advancing HIV research with pregnant women: navigating challenges and opportunities.

Authors:  Carleigh B Krubiner; Ruth R Faden; R Jean Cadigan; Sappho Z Gilbert; Leslie M Henry; Margaret O Little; Anna C Mastroianni; Emily E Namey; Kristen A Sullivan; Anne D Lyerly
Journal:  AIDS       Date:  2016-09-24       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.